[email protected]
We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. | × |
---|
2019-06-18
310
Global
Kidneys have vital role in discarding the waste from body, blood regulation and mineral homeostasis. Dysfunction of the kidney leads to chronic kidney disease and has adverse impact on rest of the body. The factors such as increasing geriatric population, rise in number of chronic kidney disease cases and prevalence of other disease in body (such as diabetes, high blood pressure, smoking, obesity and others) that risk the increase of chronic kidney disease (CKD), tends to drive the global chronic kidney disease drugs market.
In current scenario, there are no drugs/medications that can cure or reverse the effect of CKD but by controlling and curing other diseases such as high blood pressure, diabetes, anemia and others can help to treat the symptoms. Various pharmaceutical companies are researching to find drugs and better treatment process of CKD. One such example is Novadiol, a pharmaceutical company, is undergoing the clinical trials of Dendocrin to treat secondary hyperparathyroidism (SHPT) in stage 3 and 4 CKD patients.
In the United States nearly 20 million people are suffering from kidney disorders and 600,000 have kidney failure. Whereas in Brazil, 10 million people are identified to suffer from renal disorders and this incidence is growing at a rate of 10.0% every year, which is thus inducing the demand for chronic kidney disease drugs.
As per the research, major etiology of CKD is hypertension (80.0%) presented in patients followed by diabetes (33.0%) and cardiovascular diseases (11.9%) patients. The incidences of hypertension is increasing across the world including developed and developing countries. Therefore, the countries with increasing rate of diseases have higher rate CKD cases amounting to rise in demand of CKD drugs. The pharmaceutical companies and distribution companies have high growth opportunities in terms of supply of CKD drugs in the regions with rise in number of cases that are causing CKD, such as North America & Latin America.
Our Global Chronic Kidney Disease Drugs Market can be segmented on the following basis:
Based on Drug Class
Based on Distribution Channel
Based on Geography
Some of the major players included in the chronic kidney disease drugs market report are: Amgen Inc., Pfizer Inc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Sanofi S.A., GlaxoSmithKline Plc, Kissei Pharmaceutical Co. Ltd., AbbVie Inc., and Keryx Biopharmaceuticals Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
For a detailed overview send us request for CKD market report sample.
A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements
OR Call Us:+1-646-568-7747Global Injectable Drugs Market Report: Market Segmentation Based on Product Type & by Region with Forecast 2017-2030
Global Biologics Drug Discovery Market Outlook 2024: Global Opportunity and Demand Analysis, Market Forecast, 2016-2024
Global Brain Health Supplements Market Outlook 2024: Global Opportunity and Demand Analysis, Market Forecast, 2016-2024
Global Anti-Diabetic Drugs Industry: Market Segmentation By Drug Class, By Mode of Administration, By Diabetes Type, By Drug Type & by Region with Forecast 2017-2030
Hypertension Drugs Market Size: Global Industry and Demand Analysis, Trends, Market Forecast, 2016-2024
Global Organ Care System Market: Industry Research Report 2017-2025 (Perfusion System Market), Overview (Share, Revenue, Share, Size, Demand, Challenges, Key Players)